Medtronic’s Hugo still a long way from victory

Medtronic has bounced back higher than anyone had expected. Elective procedures are up and running again, pushing fourth-quarter revenues, reported yesterday, up 37% to $8.2bn.

But the company is looking to the future too, and is particularly enthusiastic about some of its forthcoming products. It has started selling its Hugo surgical robot outside the US, and a US trial in urological procedures is about to start.